Cargando…

Attenuated PDGF signaling drives alveolar and microvascular defects in neonatal chronic lung disease

Neonatal chronic lung disease (nCLD) affects a significant number of neonates receiving mechanical ventilation with oxygen‐rich gas (MV‐O(2)). Regardless, the primary molecular driver of the disease remains elusive. We discover significant enrichment for SNPs in the PDGF‐Rα gene in preterms with nCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Oak, Prajakta, Pritzke, Tina, Thiel, Isabella, Koschlig, Markus, Mous, Daphne S, Windhorst, Anita, Jain, Noopur, Eickelberg, Oliver, Foerster, Kai, Schulze, Andreas, Goepel, Wolfgang, Reicherzer, Tobias, Ehrhardt, Harald, Rottier, Robbert J, Ahnert, Peter, Gortner, Ludwig, Desai, Tushar J, Hilgendorff, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666314/
https://www.ncbi.nlm.nih.gov/pubmed/28923828
http://dx.doi.org/10.15252/emmm.201607308
Descripción
Sumario:Neonatal chronic lung disease (nCLD) affects a significant number of neonates receiving mechanical ventilation with oxygen‐rich gas (MV‐O(2)). Regardless, the primary molecular driver of the disease remains elusive. We discover significant enrichment for SNPs in the PDGF‐Rα gene in preterms with nCLD and directly test the effect of PDGF‐Rα haploinsufficiency on the development of nCLD using a preclinical mouse model of MV‐O(2). In the context of MV‐O(2), attenuated PDGF signaling independently contributes to defective septation and endothelial cell apoptosis stemming from a PDGF‐Rα‐dependent reduction in lung VEGF‐A. TGF‐β contributes to the PDGF‐Rα‐dependent decrease in myofibroblast function. Remarkably, endotracheal treatment with exogenous PDGF‐A rescues both the lung defects in haploinsufficient mice undergoing MV‐O(2). Overall, our results establish attenuated PDGF signaling as an important driver of nCLD pathology with provision of PDGF‐A as a protective strategy for newborns undergoing MV‐O(2).